scholarly journals Corrigendum to ‘Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials’ [ Eur J Heart Fail 2020;11:2160–2171]

2021 ◽  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
Omecamtiv Mecarbil ◽  
Baseline Characteristics

scholarly journals Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction

2020 ◽  
Vol 8 (4) ◽  
pp. 329-340 ◽  
Author(s):  
John R. Teerlink ◽  
Rafael Diaz ◽  
G. Michael Felker ◽  
John J.V. McMurray ◽  
Marco Metra ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
Omecamtiv Mecarbil

scholarly journals Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure

2020 ◽  
Vol 13 (12) ◽  
Author(s):  
G. Michael Felker ◽  
Scott D. Solomon ◽  
John J.V. McMurray ◽  
John G.F. Cleland ◽  
Siddique A. Abbasi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Symptom Score ◽  
Summary Score ◽  
Total Symptom Score ◽  
Reduced Ejection Fraction ◽  
Related Quality ◽  
Health Related ◽  
Omecamtiv Mecarbil

Background: Chronic heart failure with reduced ejection fraction impairs health-related quality of life (HRQL). Omecamtiv mecarbil (OM)—a novel activator of cardiac myosin—improves left ventricular systolic function and remodeling and reduces natriuretic peptides. We sought to evaluate the effect of OM on symptoms and HRQL in patients with chronic heart failure with reduced ejection fraction and elevated natriuretic peptides enrolled in the COSMIC-HF trial (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure). Methods: Patients (n=448) were randomized 1:1:1 to placebo, 25 mg of OM BID, or to pharmacokinetically guided dose titration (OM-PK) for 20 weeks. The Kansas City Cardiomyopathy Questionnaire was administered to assess HRQL at baseline, 16 weeks, and 20 weeks. The primary scores of interest were the Total Symptom Score, Physical Limitation Scale, and Clinical Summary Score. Results: Mean change in score from baseline to 20 weeks for the Total Symptom Score was 5.0 (95% CI, 1.8–8.1) for placebo, 6.6 (95% CI, 3.4–9.8) for OM 25 mg ( P =0.32 versus placebo), and 9.9 (95% CI, 6.7–13.0) for OM-PK ( P =0.03 versus placebo); for the Physical Limitation Scale, it was 3.1 for placebo (95% CI, −0.3 to 6.6), 6.0 (95% CI, 3.1–8.9) for OM 25 mg ( P =0.12), and 4.3 (95% CI, 0.7–7.9) for OM-PK ( P =0.42); for the Clinical Summary Score, it was 4.1 (95% CI, 1.4–6.9) for placebo, 6.3 (95% CI, 3.6–9.0) for OM 25 mg ( P =0.19), and 7.0 (95% CI, 4.1–10.0) for OM-PK ( P =0.14). Differences between OM and placebo were greater in patients who were more symptomatic at baseline. Conclusions: HRQL as measured by the Total Symptom Score improved in patients with heart failure with reduced ejection fraction assigned to the OM-PK group relative to placebo. Ongoing trials are prospectively testing whether OM improves symptoms and HRQL in heart failure with reduced ejection fraction. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01786512.

Exercise Dynamic of Patients with Chronic Heart Failure and Reduced Ejection Fraction

2021 ◽  
Vol 23 (7) ◽  
Author(s):  
Sara Rovai ◽  
Irene Mattavelli ◽  
Elisabetta Salvioni ◽  
Ugo Corrà ◽  
Gaia Cattadori ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Reduced Ejection Fraction
Sign in / Sign up

Export Citation Format

Share Document